A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects
Latest Information Update: 11 Jan 2019
At a glance
- Drugs Salmeterol (Primary)
- Indications Subcutaneous fat disorders
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms AbCONTOUR2
- Sponsors Neothetics
- 10 Nov 2016 Status changed from active, no longer recruiting to completed, as per Neothetics media release.
- 14 Dec 2015 Primary endpoint has not been met. (Change in the patient reported photonumeric score), as per Neothetics media release.
- 14 Dec 2015 Primary endpoint has not been met. (Change in the clinician reported global abdominal perception score), as per Neothetics media release.